论文部分内容阅读
目的分析头颈部鳞癌组织多药耐药基因产物Ｐ糖蛋白（Ｐ１７０）的表达及临床意义。方法应用ＪＳＢ－１单克隆抗体。采用免疫组化（ＳＰ）法对３０例头颈部鳞癌（口腔癌１４例，唇癌１０例，皮肤癌６例）患者ｍｄｒ１基因产物Ｐ１７０进行检测。结果Ｐ１７０表达率为６３．３％，其中初诊组患者Ｐ１７０阳性率为４７．４％，复发组患者９０．９％。初诊阳性率明显低于复发组阳性率（Ｐ＜０．０１）。以唇癌Ｐ１７０阳性表达率最低。另外对１０例唇癌病人进行初步观察，Ｐ１７０表达阴性组化疗有效率（ＣＲ＋ＰＲ）９２％，显著高于阳性组４７．６％。结论提示头颈部鳞癌多药耐药与Ｐ１７０表达有关。
Objective To analyze the expression and clinical significance of multidrug resistance gene product P-glycoprotein (P170) in head and neck squamous cell carcinoma. The method utilizes the JSB-1 monoclonal antibody. Immunohistochemical (SP) method was used to detect mdr1 gene product P170 in 30 head and neck squamous cell carcinomas (14 oral cancers, 10 lip cancers, and 6 skin cancers). Results The expression rate of P170 was 63.3%. The positive rate of P170 was 47.4% in the newly diagnosed group and 90.9% in the relapsed group. The positive rate of new diagnosis was significantly lower than that of recurrence group (P<0.01). The P170 positive expression rate was lowest in lip cancer. In addition, 10 patients with lip cancer were initially observed. The effective rate of chemotherapy in the P170-negative group (CR+PR) was 92%, which was significantly higher than that of the positive group (47.6%). The results suggest that multidrug resistance in head and neck squamous cell carcinoma is related to the expression of P170.